SCHEMBL3243045

SCHEMBL3243045

NC(=O)c1c[nH]c2c(=O)[nH]c3ccccc3c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM3 Q86V86 2/20 0.59
PIM1 P11309 1/20 0.59
ALDH1A1 P00352 3/20 0.55
ATM Q13315 1/20 0.55
CHEK1 O14757 2/20 0.44
KDM4E B2RXH2 4/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPT P10636 2/20 0.42
IDE P14735 1/20 0.42
MPI P34949 1/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
GPR84 Q9NQS5 1/20 0.42
PARP1 P09874 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TNKS O95271 2/20 0.42
TNKS2 Q9H2K2 2/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4761273 0.90 PIM3 (0.50) PIM3PIM1ALDH1A1ATMCHEK1
SCHEMBL14624992 0.87 PIM3 (0.48) PIM3PIM1ALDH1A1ATMCHEK1
SCHEMBL3247782 0.87 KDM4E (0.54) PIM3PIM1ALDH1A1CHEK1KDM4E
SCHEMBL3251592 0.85 PBRM1 (0.55) PIM3PIM1ALDH1A1CHEK1KDM4E
SCHEMBL3245579 0.83 KDM4E (0.44) PIM3PIM1ALDH1A1CHEK1KDM4E
SCHEMBL14624979 0.82 CHEK1 (0.44) PIM3PIM1ALDH1A1CHEK1KDM4E
SCHEMBL3245630 0.82 EGFR (0.45) PIM3PIM1ALDH1A1CHEK1KDM4E
SCHEMBL13356384 0.82 NR4A2 (0.58) PIM3PIM1ALDH1A1KDM4EMAPT
SCHEMBL3245695 0.82 PIM3 (0.43) PIM3PIM1ALDH1A1CHEK1KDM4E
SCHEMBL3249869 0.80 CFTR (0.60) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP disclosed
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP disclosed
EP-2154189-A1 Phenol composition and thermoplastic polymer composition comprising the composition Sumitomo Chemical Company, Limited (JP) 2010-02-17 EP disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed
EP-1899335-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2008-03-19 EP disclosed
WO-2007003611-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 PIM3 337/4885PIM1 279/4885ALDH1A1 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.